Sarcoma Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028
Global Sarcoma Drugs Market: Overview
A sarcoma, a rare form of cancer, differs from the more common carcinomas in one major way – they occur in a different type of tissue known as connective tissue. Those are essentially cells that support or connect other types of tissue in the human body. Sarcoma is highly common in muscles, bones, fats, nerves, cartilage, and blood vessels in one’s arms and legs. They can, however, also happen in other areas in the body.
The report on the global sarcoma drugs market finds that the market would rise at a healthy clip owing to emergence and acceptance of novel sarcoma drugs for treatment, a solid pipeline in the development phase, increasing allocation on research and development, and growing occurrence of soft tissue sarcomas.
Global Sarcoma Drugs Market: Drivers and Restraints
At present, chemotherapy regimens and targeted therapy are the two popular form of cure in the sarcoma drugs market. Between the two, the targeted therapy is predicted to see greater uptake in the near term because of its greater efficacy. Such treatments make use of drugs or antibodies formulated from the immune system to thwart proliferation of harmful cancer cells while leaving out the normal cells undamaged.
Other popular forms of cure in the sarcoma drugs market are surgeries in which the tumor is removed from the body or radiation in which the tumor cell is shrunk before surgery or the remaining cells killed post.
A noticeable trend in the global sarcoma drugs market is money and efforts being expended for numerous immune-oncology agents. The sarcoma drugs has also received a major boost from the approval of new chemotherapy drugs, namely Johnson & Johnson’s Yondelis and Eisai’s Halaven. They have a far greater efficacy than the earlier anthracycline-based treatment regimens.
Global Sarcoma Drugs Market: Trends and Opportunities
There are 50 different types of sarcomas known today. Those can be broadly classified into bone sarcoma (osteosarcoma) and soft tissue sarcoma. The soft tissue sarcoma currently account for almost 87.0% of all sarcoma cases. Bone sarcomas, which are considered malignant, account for just 13.0% of all cases. Hence, the soft tissue sarcomas currently present maximum opportunity in the global sarcoma drugs market.
There are almost 45 drugs in the clinical pipeline in the global sarcoma drugs market. Besides, cancer vaccines and gene therapy are also emerging as potential treatments for soft tissue cancer. Numerous monoclonal antibodies and small molecules are in active development in Phase I and II trials as well.
Global Sarcoma Drugs Market: Regional Analysis
From a geographical standpoint, the U.S. at present forms the nerve center of the global sarcoma drugs market. Presence of a clutch of key players in the region, high government allocations towards research and development for sarcoma drugs, higher per capita medical spends of people, state-of-the-art research and healthcare facilities, and most importantly more number of sarcoma cases in the region have majorly fuelled its market.
The European Union region is also a crucial sarcoma drugs market because of the greater understanding of tumor microenvironment predicted to occur in the next couple of years thereby resulting in development of new patient-specific therapies.
Global Sarcoma Drugs Market: Competitive Landscape
Some of the prominent participants in the global sarcoma drugs market that have been profiled in the report are Novartis, Amgen, Eli Lilly, Pfizer, Eisai, Johnson & Johnson, and Bayer. Besides throwing light on their products, the report also studies late-stage pipeline products of certain companies. The report observes savvy companies are embarking upon collaborations for conducting clinical trials, development, and broader product portfolios to bolster their positions in the global sarcoma drugs market.
The study presents reliable qualitative and quantitative insights into:
The regional analysis covers:
The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.
Highlights of the report:
Note: Immense care has been taken to present data with the highest levels of accuracy in all TMRResearch reports. Nevertheless, recent developments related to market/vendor landscape may take time to reflect in the analysis.
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report